Results of Renal Transplantation in Patients With Schistosoma Infection

Abstract

Patients with schistosomal infection are suitable recipients for kidney transplantation, although they are at risk for urological complications. Unlike other infectious diseases, such as tuberculosis, the risk of recurrence due to reactivation of chronically hosted pathogens seems to be low or absent in patients who received antischistosomal chemotherapy at the pre-transplant evaluation. Long-term urological followup is recommended, including urethrocystoscopy, because of the theoretically increased risk for bladder malignancy.

Urological complications after living‐donor renal transplantation

“…The potential impact of urinary bilharziasis has been addressed by several studies [29–33] with controversial conclusions. In the present series the rate of complications among patients with evidence of bilharziasis was 10%, while that among patients with no evidence was 7.4%; this difference was not statistically significant in the univariate analysis.…”

Renal transplantation: the impact of schistosomiasis

“…Bout et al [20,21] reported a curative and protective effect of cyclosporin against primary and secondary S. mansoni in mice and rats. However, this observation was not supported by others, as schistosomal re‐infection was diagnosed in patients receiving cyclosporin [10,11,13].…”

“…There was no correlation between the schistosomal antibody titre and incidence or frequency of graft rejection [13]. Gazzinelli et al [14] showed that the titres of anti‐schistosomal antibodies decline and stabilize as the infection progresses.…”

“…Hepatitis antigenaemia is commoner in schistosomal patients [10,11,13]; although Dusheiko et al [15] reported that patient survival was less for hepatitis B virus carriers, because of the increased incidence of liver cell failure and hepatocellular carcinoma, other studies failed to support this observation [10,11].…”

Infections among pediatric transplant candidates: An approach to decision‐making

“…For Strongyloides, 55% of our panel recommended an intermediate delay (C; 2) ( Table 4). [33][34][35][36][37][38] The panel noted that the approach to Regardless of the reason for the urgency, the presence of bridging therapies for several organs such as dialysis or VAD also needs to be weighed in these situations. reported .…”